Tesamorelin
GHRH analogue studied in vitro.
Specification
- Catalogue ID: SP143
- HPLC purity: 99.6%
- Formulation: Lyophilized
- Quantity: 10mg / Vial
- Price: £71.00
GH-axis research · stabilised GHRH analogue pharmacology
Tesamorelin is a synthetic stabilised analogue of human GHRH(1-44)-NH₂, incorporating trans-3-hexenoic acid conjugated to the N-terminus of the full-length 44-amino-acid GHRH sequence. This modification confers increased resistance to dipeptidylpeptidase-IV (DPP-IV) cleavage while retaining full agonist activity at the pituitary GHRH receptor.
In GHRH-receptor binding assays and pituitary cell-stimulation studies, tesamorelin demonstrates high-affinity GHRHR engagement and cAMP-dependent GH secretion with a more sustained kinetic profile than unmodified GHRH(1-29). It is used as a research tool to probe GH-axis pharmacology.
Cell-culture and ex-vivo studies have used tesamorelin to examine downstream effects of GHRH-receptor stimulation on GH-IGF-1 axis signalling, including IGF-1 production in hepatocyte and adipocyte models. Its well-characterised pharmacology makes it a valuable reference compound in GHRH-analogue comparative studies.
No physiological or therapeutic properties are claimed; supplied for in-vitro laboratory research use only.
Compound identity
- CAS number: 218949-48-9
- Molecular formula: C₂₂₁H₃₆₆N₇₂O₆₇S
- Molecular weight: 5135.84 Da
- Solubility: Soluble in water
- Reconstitution: Add 2 mL bacteriostatic water per vial; swirl gently until dissolved
For in-vitro laboratory research use only. Not for human or veterinary use, consumption, or therapeutic application. No medical claims are made.